Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study
AuthorsFindling, Robert L.
Johnson, Jacqueline L.
Frazier, Jean A.
Hamer, Robert M.
Lieberman, Jeffrey A.
McNamara, Nora K.
Hlastala, Stefanie A.
Maloney, Ann E.
Kaufman, Emily Michael
UMass Chan AffiliationsDepartment of Psychiatry
Document TypeJournal Article
Psychiatric Status Rating Scales
MetadataShow full item record
AbstractOBJECTIVE: To examine the long-term safety and efficacy of three antipsychotics in early-onset schizophrenia spectrum disorders. METHOD: Patients (8 to 19 years old) who had improved during an 8-week, randomized, double-blind acute trial of olanzapine, risperidone, or molindone (plus benztropine) were eligible to continue on the same medication for up to 44 additional weeks under double-blind conditions. Adjunctive medications were allowed according to defined algorithms. Standardized symptom, safety, and functional assessments were conducted every 4 weeks. RESULTS: Of the 116 youths randomized in the acute trial, 54 entered maintenance treatment (molindone, n = 20; olanzapine, n = 13; risperidone, n = 21). Fourteen (26%) completed 44 weeks of treatment. Adverse effects (n = 15), inadequate efficacy (n = 14), or study nonadherence (n = 8) were the most common reasons for discontinuation. The three treatment arms did not significantly differ in symptom decrease or time to discontinuation. Akathisia was more common with molindone and elevated prolactin concentrations more common with risperidone. Although weight gain and metabolic adverse events had occurred more often with olanzapine and risperidone during the acute trial, no significant between-drug differences emerged in most of these parameters during maintenance treatment. CONCLUSIONS: Only 12% of youths with early-onset schizophrenia spectrum disorders continued on their originally randomized treatment at 52 weeks. No agent demonstrated superior efficacy, and all were associated with side effects, including weight gain. Improved treatments are needed for early-onset schizophrenia spectrum disorders. Clinical trial registry information-Treatment of Schizophrenia and Related Disorders in Children and Adolescents; URL: http://www.clinicaltrials.gov, unique identifier: NCT00053703. Elsevier Inc. All rights reserved.
SourceJ Am Acad Child Adolesc Psychiatry. 2010 Jun;49(6):583-94; quiz 632. Epub 2010 May 1. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/45897
Related ResourcesLink to Article in PubMed